4 recruiting, 2 not yet recruiting, 1 active not recruiting. 7 Phase 1, 4 Phase 2.
By phase and status
Follow FBD Biologics Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Phase 1 Study of HCB303 in Participants With Advanced Malignancies
HCB303 - Advanced Malignancies | Phase 1 | Not yet recruiting | 150 | 2027-02-28 | 2026-10-05 |
Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma
Zolbetuximab, Oxaliplatin + 5-Fluorouracil/Leucovorin, CAPOX (oxaliplatin/capecitabine) - GC/GEJC | Phase 1 / Phase 2 | Not yet recruiting | 40 | 2026-06-01 | 2026-07-02 |
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
HCB101, Pembrolizumab - HNSCC | Phase 1 / Phase 2 | Recruiting | 50 | 2025-08-13 | 2026-07-06 |
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
HCB101, Bevacizumab, Cetuximab (Erbitux) - CRC | Phase 1 / Phase 2 | Recruiting | 40 | 2025-05-14 | 2025-10-02 |
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
HCB301 - Advanced Solid Tumor, Refractory Hodgkin Lymphoma | Phase 1 | Recruiting | 50 | 2025-04-02 | 2026-04-13 |
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
HCB101, Trastuzumab, Pertuzumab - Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | 500 | 2025-03-13 | 2026-02-04 |
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
HCB101 - Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma | Phase 1 | Recruiting | 80 | 2023-10-02 | 2026-02-04 |
Conditions studied
Camurati-Engelmann Syndrome (1) · Hodgkin Disease (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Interventions
Fluorouracil (3) · Leucovorin (3) · Oxaliplatin (3) · Bevacizumab (2) · Capecitabine (2) · Cetuximab (2) · Irinotecan (2) · pembrolizumab (2) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Etoposide (1) · Folfox protocol (1) · Paclitaxel (1) · Ramucirumab (1) · Trastuzumab (1)
Countries
Taiwan (4) · China (3) · United States (2)
Top investigators
Hung-Chih Hsu (1) · Mu-Hsin Chang (1)